Brian I. Rini, GU Oncology Now Journalist Profile

Articles

Biomarker-informed care for patients with renal cell carcinoma - Nature Cancer

1 week ago | nature.com | Brian I. Rini |Scott M. Haake

AbstractKidney cancer is a commonly diagnosed cancer in adults, and clear cell renal cell carcinoma (ccRCC) is the most common histological subtype. Immune checkpoint inhibitors have revolutionized care for patients with ccRCC, either as adjuvant therapy or combined with other agents in advanced disease. However, biomarkers to predict therapeutic benefits are lacking.
Belzutifan vs Everolimus Trial Data in Advanced RCC Care - Brian Rini

Oct 30, 2024 | urotoday.com | Brian I. Rini

Read the Full Video TranscriptPedro Barata: Hi there. I'm Pedro Barata, a genitourinary oncologist at University Hospitals Seidman Cancer Center. I'm very, very happy to be joined today by Dr. Brian Rini. He doesn't really need an introduction at this point, but Dr. Rini is the Chief of Clinical Trials and Ingram Professor of Cancer Research at Vanderbilt Ingram Cancer Center in Nashville. Brian, thank you so much for joining us. Brian Rini: Thanks for having me. Pedro Barata: Right.
Dr Rini on the Background of a Biomarker Analysis of KEYNOTE-426 in RCC

Jul 23, 2024 | onclive.com | Brian I. Rini

CommentaryVideoJuly 23, 2024Author(s):Brian I. Rini, MD, FASCO, discusses an analysis of clustering from the KEYNOTE-426 study in patients with advanced renal cell carcinoma. Brian I.
Dr Rini on a Biomarker Analysis of KEYNOTE-426 Using Subtype Clustering RCC

Jul 17, 2024 | onclive.com | Brian I. Rini

Brian I. Rini, MD, FASCO, Ingram Professor of Medicine, Department of Medicine, Division of Hematology Oncology, Vanderbilt University, discusses findings from an analysis of subtype clustering from the phase 3 KEYNOTE-426 study (NCT02853331) evaluating pembrolizumab (Keytruda) plus axitinib (Inlyta) vs sunitinib (Sutent) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Dr Rini on a Biomarker Analysis for Pembrolizumab/Axitinib in Advanced RCC

Jul 10, 2024 | onclive.com | Brian I. Rini

Brian I. Rini, MD, FASCO, Ingram Professor of Medicine, Department of Medicine, Division of Hematology Oncology, Vanderbilt University, discusses findings from an exploratory biomarker analysis of the phase 3 KEYNOTE-426 study (NCT02853331) evaluating pembrolizumab (Keytruda) plus axitinib (Inlyta) vs sunitinib (Sutent) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Dr Rini on the FDA Approval of Belzutifan in Relapsed/Refractory RCC

Mar 13, 2024 | onclive.com | Brian I. Rini

Brian I. Rini, MD, FASCO, Ingram Professor of Medicine, Department of Medicine, Division of Hematology Oncology, Vanderbilt University, chief, Clinical Trials, Vanderbilt-Ingram Cancer Center, make sure the institution name is changed in the lower third too discusses the importance of the FDA approval of belzutifan (Welireg) in patients with relapsed/refractory renal cell carcinoma (RCC).
Survival Advantage of Adjuvant IO ‘Big News’ in Renal Cancer

Mar 13, 2024 | mdedge.com | Brian I. Rini

Publish date: March 13, 2024 This transcript has been edited for clarity. Hi. I’m Brian Rini. I’m an Ingram Professor of Medicine at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. I’m going to talk to you briefly today about some major highlights in renal cancer from the Genitourinary (GU) Cancer Symposium that was just held. I think there’s three main areas: adjuvant therapy in kidney cancer, frontline therapy in advanced disease, and the refractory space.
Survival Advantage 'Big News' in Renal Cancer

Mar 12, 2024 | medscape.com | Brian I. Rini

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. My Alerts You have already selected for My Alerts Add Other Topics Click the topic below to receive emails when new articles are available. Add You've successfully added to your alerts. You will receive email when new content is published. Manage Email Alerts
Dr Rini on the Utility of Belzutifan in RCC

Feb 29, 2024 | newsbreak.com | Brian I. Rini

By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy
Dr Rini on the Utility of Belzutifan in RCC

Feb 29, 2024 | onclive.com | Brian I. Rini

Brian I. Rini, MD, FASCO, Ingram Professor of Medicine, Division of Hematology Oncology, chief, Clinical Trials, Vanderbilt-Ingram University Cancer Center, discusses the background that led to the FDA approval of belzutifan (Welireg) for the treatment of patients with advanced renal cell carcinoma (RCC). Belzutifan is a well-tolerated medication, generally associated with better tolerability than most TKIs, Rini begins.